AKT1 and neoplasm: EGFRvIII likely bypasses the proliferative inhibition caused by Olig1/2 loss through constitutive activation of downstream signaling pathways (e.g., PI3K/AKT/mTOR and MAPK/ERK), thereby providing alternative survival and proliferative signals for tumor cells.